Report results from the ampreloxetine Phase 3 study in symptomatic neurogenic orthostatic hypertension
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 23 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Ampreloxetine (norepinephrine reuptake inhibitor (NRI)) for symptomatic neurogenic orthostatic hypertension (nOH) Phase 3 study expected to report results in Q3 2021”
What we found
Evidence strength A What the grades mean
The 10-K says the Phase 3 SEQUOIA ampreloxetine results were reported in September 2021, within Q3 2021, though they missed the primary endpoint.
-
A Theravance Biopharma, Inc. 8-K filed 2021-11-03
“reported Phase 3 top-line results (Study 0169 - read more about the data here).” ✓ confirmed on the page
-
A Theravance Biopharma, Inc. 10-K filed 2022-02-28
“in September 2021, we reported that results from our four-week Phase 3 study (SEQUOIA) of ampreloxetine, our norepinephrine reuptake inhibitor, did not meet its primary endpoint for assessing safety and efficac” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Ampreloxetine Phase 3 nOH study results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Theravance Biopharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C583107-024225 · Corrections policy